The U.S. biosimilars market will gain momentum from the increasing government support to adopt biosimilars in the healthcare sectors. According to a report by Fortune Business Insights, titled, “Biosimilars: U.S. Market Analysis, Insights and Forecast, 2019-2026,” the U.S. biosimilars market is projected to reach US$ 17,696.0 Mn by 2026. The report provides valuable insights into the drivers influencing growth of the market. As per the report, the U.S. biosimilars market is anticipated to report an impressive CAGR of 54.7% during the forecast period. The report also states that the U.S. market was valued at US$ 436.1 Mn in 2018.
some of the key players in the global U.S. biosimilars market:
- Hoffmann-La Roche Ltd.
- AbbVie Inc.
- Merck & Co.
- Celltrion Inc.
- Coherus BioSciences, Inc.
- Teva Pharmaceutical Industries Ltd.
- Eli Lilly and Company
Browse Summary for this report@ https://www.fortunebusinessinsights.com/industry-reports/u-s-biosimilars-market-100990
Increased Research and Development Initiatives to Drive the Market
Biosimilars are the copies of original products. Due to the high cost of pharmaceutical drugs, healthcare facilities are not accessible to people from every economical stratum. This is where biosimilars come to recuse. Being an identical copy, biosimilars help in treating chronic diseases like cancer and arthritis in an effective manner just as original medications do. The market is likely to grow during the forecast period because of an increasing demand from the masses. Also, a rise in research and development initiatives by prominent organizations have increased market opportunities. This has led to tough competition in the U.S. biosimilars market.
Get Sample PDF Brochure@ https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/u-s-biosimilars-market-100990
Autoimmune Diseases Segment Projected to Dominate the Market in the U.S.
The U.S. biosimilars market is classified into three segments, namely, by distribution channel, by disease indication, and by drug class. By distribution channel, the market is grouped into online pharmacy, hospital pharmacy, and retail pharmacy. In terms of disease indication, the market is divided into cancer and autoimmune diseases such as arthritis, neutropenia, psoriasis, and others. In 2018, the autoimmune diseases held a market share of 92.0%. The segment is anticipated to remain in the leading position the U.S. biosimilars market during the forecast period. Factors like increasing adoption of biosimilars, rise in the prevalence of autoimmune diseases, and availability of limited drugs are likely to boost the segment. The Centers of Disease Control and Prevention declared that approximately 26% adults are estimated to have arthritis by 2040. This in turn, will increase the demand for biosimilars to treat arthritis. Moreover, treatment of cancer is expensive in the U.S. Combined with this, constant investments in research and development and rise in the adoption of sedentary lifestyle are projected to favor growth of the cancer segment throughout the forecast period in the U.S.
Related Reports:
Rapid Advancements in Infant Care Devices Market to Fuel Revenues Through 2020-2026
According to a report by Fortune Business Insights, titled, “Biosimilars: U.S. Market Analysis, Insights and Forecast, 2019-2026,” the U.S. biosimilars market is projected to reach US$ 17,696.0 Mn by 2026.
The report provides valuable insights into the drivers influencing growth of the market.
The report also states that the U.S. market was valued at US$ 436.1 Mn in 2018.some of the key players in the global U.S. biosimilars market:Hoffmann-La Roche Ltd.AbbVie Inc.Merck & Co.Celltrion Inc.Coherus BioSciences, Inc.Teva Pharmaceutical Industries Ltd.Eli Lilly and Company Browse Summary for this report@ https://www.fortunebusinessinsights.com/industry-reports/u-s-biosimilars-market-100990Increased Research and Development Initiatives to Drive the MarketBiosimilars are the copies of original products.
Due to the high cost of pharmaceutical drugs, healthcare facilities are not accessible to people from every economical stratum.
Being an identical copy, biosimilars help in treating chronic diseases like cancer and arthritis in an effective manner just as original medications do.
The market is likely to grow during the forecast period because of an increasing demand from the masses.
Market Analysis: Global Traveler's Diarrhea Treatment MarketTraveler's diarrhea treatment market is growing at a substantial CAGR of 7.4% in the forecast period of 2020-2027.
This rise in market value can be attributed to the increasing cases of traveler’s diarrhea; which is boosting the traveler’s diarrhea treatment market.Global Traveler's Diarrhea Treatment Market By Drugs Class (Anti-Motility Agents, Antibiotics and Others), Drugs (Lomotil, Imodium, Pepto-Bismol, Rifaximin and Others), Route of Administration (Oral and Parenteral), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), End-Users (Hospitals, Homecare, Specialty Clinics and Others), Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa) - Industry Trends and Forecast to 2027Download Sample Report with related Graphs and Figures@ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-travelers-diarrhea-treatment-marketMarket Definition: Global Traveler's Diarrhea Treatment MarketTraveler's diarrhea is a digestive tract disorder characterized by an intestinal infection that generally occurs when a person consume contaminated food and water.
This infection generally spreads through intestinal pathogens contracted while traveling where here the climatic conditions and sanitary practices are different from their home.
Symptoms include loose stools, abdominal cramps, nausea and vomiting.According to Centers for Disease Control and Prevention, travelers’ diarrhea (TD) is the most prevalent and predictable travel related illness worldwide.
The prevalence rate ranges from 30% to 70% of travelers globally, depending on the destination and season of travel.Market Drivers· Worldwide growing tourism is accelerating the market growth for traveler's diarrhea treatment· Unhealthy lifestyle of people will drive the market growth in the forecast period· Poor sanitation in developing and underdeveloped countries is acting as catalyst to market growth· Rise in the healthcare expenditure globally will also boost the market growthMarket Restraints· Lack of awareness amongst people regarding sanitation in developing nations as well as underdeveloped nations will restraint the market growth· Side effects of the drugs such as constipation and headache may hamper the market growth· Unavailability of skilled professionals will restrict the market growth for traveler's diarrhea treatmentClick here for Detailed Analysis Report https://www.databridgemarketresearch.com/reports/global-travelers-diarrhea-treatment-marketCompetitive Analysis:Global Traveler's diarrhea treatment market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market.
The report includes market shares of traveler's diarrhea treatment for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.Key Market Players:The key market players in the traveler's diarrhea treatment market are Bayer AG, Merck & Co., Inc, Johnson & Johnson Services, Inc, Novartis AG, Valneva SE, Shanghai United Cell Biotechnology Co.,Ltd, PaxVax, Inc, Immuron, Salix Pharmaceuticals, F. Hoffmann-La Roche Ltd, Basilea Pharmaceutica Ltd, Eli Lilly and Company, Delcath Systems Inc, BridgeBio Inc, Incyte Corporation, Agios, Inc among others.Access Full Report@ https://www.databridgemarketresearch.com/checkout/buy/singleuser/global-travelers-diarrhea-treatment-marketGlobal AIDS Treatment Market Scope and Market Size:Traveler's diarrhea treatment market is segmented of the basis of drugs class, drugs, route of administration, distribution channel and end user.
Market Analysis and Insight: Europe Anticoagulation Therapy MarketEurope Anticoagulation Therapy Market By Treatment (Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Arterial Thromboembolism (AT), Stroke, Others), Therapeutic Class (Novel Oral Anticoagulants (NOAC), Heparin, Vitamin K Antagonists, Others), Drug Type (Bivalirudin, Dabigatran , Edoxaban, Betrixaban, Rivaroxaban , Apixaban, Enoxaparin, Dalteparin, Others), Route of Administration (Oral, Parenteral), Therapeutic Area (Cardiovascular, Respiratory, Oncology, Nephrology, CNS, Others), Procedure (Pre-Surgical Procedures, Post-Surgical Procedures, Kidney Dialysis, Heart Valve Replacement), Type (Generics, Branded), End User (Hospitals, Clinics, Homecare, Ambulatory Surgical Centres, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Country (Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Rest of Europe) – Industry Trends and Forecast to 2026Anticoagulation therapy is a medication used in prevention of blood clots formation and to uphold blood vessels open.
Anticoagulants are usually called as blood thinners but in reality it do not thin the blood but only helps to prevent or to reduce blood clot formation/thrombi.
There are various anticoagulants available in the market such as vitamin K antagonists, heparin and novel oral anticoagulation which is used for prophylaxis/treatment of various thromboembolic disorders, such as heart attack (myocardial infarction), stroke and deep venous thrombosis (DVT).Europe anticoagulation therapy market is projected to register a substantial CAGR in the forecast period of 2019 to 2026.Get a Sample Copy of report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=europe-anticoagulation-therapy-marketSegmentation: Europe Anticoagulation Therapy MarketEurope anticoagulation therapy market is segmented into nine notable segments which are treatment, therapeutic class, drug type, route of administration, therapeutic area, procedure, type, end user and distribution channel.On the basis of treatment, the market is segmented into deep vein thrombosis (DVT), pulmonary embolism (PE), arterial thromboembolism (AT), stroke and othersOn the basis of therapeutic class, the market is segmented into novel oral anticoagulation (NOAC), heparin, vitamin k antagonists and othersOn the basis of drug type, the market is segmented into bivalirudin, dabigatran, edoxaban, betrixaban, rivaroxaban, apixaban, enoxaparin, delteparin and othersOn the basis of route of administration, the market is segmented into oral and injectableOn the basis of therapeutic area, the market is segmented into cardiovascular diseases, oncology, respiratory, nephrology, CNS and othersOn the basis of procedure, the market is segmented into pre-surgical procedures, post-surgical procedures, kidney dialysis and heart valve replacementOn the basis of type, the market is segmented into generics and brandedOn the basis of end user, the market is segmented into hospitals, clinics, homecare, ambulatory surgical centers and othersOn the basis of distribution channel, the market is segmented into hospital pharmacy, retail pharmacy and online pharmacyCompetitive Analysis: Europe Anticoagulation Therapy MarketSome of the major players operating in the Europe anticoagulation therapy market are Hikma Pharmaceuticals PLC, Mylan N.V., Teva Pharmaceutical Industries Ltd., Novartis AG, Eisai Co., Ltd., Pfizer Inc., Sanofi, F. Hoffmann-La Roche Ltd, Fresenius Kabi AG, Aspen Holdings, Shanghai Fosun Pharmaceutical（Group）Co., Ltd. , Cipla Inc, Johnson & Johnson Services, Inc., Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, DAIICHI SANKYO COMPANY, LIMITED, Eagle Pharmaceuticals, Inc., Endo Pharmaceuticals Inc, Mitsubishi Tanabe Pharma Corporation, Portola Pharmaceuticals, Inc., Taro Pharmaceutical Industries Ltd., among others.Get Detailed Table of Contents @ https://www.databridgemarketresearch.com/toc/?dbmr=europe-anticoagulation-therapy-marketRecent DevelopmentsIn September 2018, Sanofi announced Health got Canada approval for Lovenox’s (enoxaparin sodium) new indication toprevent thrombus formation in the extra-corporeal circulation during haemodialysis in patients who are having end stage kidney disease (ESKD).
This will attract the potential consumers helping in the growth of the company.In August 2018, Bayer AG received the European Commission (EC) approval for Xarelto (rivaroxaban) 2.5 mg.
It is indicated for reduction of chances of cardiovascular situations such as stroke/ heart attack in patients with chronic coronary artery disease (CAD), cardiovascular (CV) death, and peripheral artery disease (PAD).
This approval will help the company to develop anticoagulant business in European countries.In June 2015, Daiichi Sankyo Company, Limited received the EU approval for LIXIANA (edoxaban).
Market Analysis and Insight: Europe Anticoagulation Therapy MarketEurope Anticoagulation Therapy Market By Treatment (Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Arterial Thromboembolism (AT), Stroke, Others), Therapeutic Class (Novel Oral Anticoagulants (NOAC), Heparin, Vitamin K Antagonists, Others), Drug Type (Bivalirudin, Dabigatran , Edoxaban, Betrixaban, Rivaroxaban , Apixaban, Enoxaparin, Dalteparin, Others), Route of Administration (Oral, Parenteral), Therapeutic Area (Cardiovascular, Respiratory, Oncology, Nephrology, CNS, Others), Procedure (Pre-Surgical Procedures, Post-Surgical Procedures, Kidney Dialysis, Heart Valve Replacement), Type (Generics, Branded), End User (Hospitals, Clinics, Homecare, Ambulatory Surgical Centres, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Country (Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Rest of Europe) – Industry Trends and Forecast to 2026Anticoagulation therapy is a medication used in prevention of blood clots formation and to uphold blood vessels open.
Anticoagulants are usually called as blood thinners but in reality it do not thin the blood but only helps to prevent or to reduce blood clot formation/thrombi.
There are various anticoagulants available in the market such as vitamin K antagonists, heparin and novel oral anticoagulation which is used for prophylaxis/treatment of various thromboembolic disorders, such as heart attack (myocardial infarction), stroke and deep venous thrombosis (DVT).Europe anticoagulation therapy market is projected to register a substantial CAGR in the forecast period of 2019 to 2026.Get a Sample Copy of report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=europe-anticoagulation-therapy-marketSegmentation: Europe Anticoagulation Therapy MarketEurope anticoagulation therapy market is segmented into nine notable segments which are treatment, therapeutic class, drug type, route of administration, therapeutic area, procedure, type, end user and distribution channel.On the basis of treatment, the market is segmented into deep vein thrombosis (DVT), pulmonary embolism (PE), arterial thromboembolism (AT), stroke and othersOn the basis of therapeutic class, the market is segmented into novel oral anticoagulation (NOAC), heparin, vitamin k antagonists and othersOn the basis of drug type, the market is segmented into bivalirudin, dabigatran, edoxaban, betrixaban, rivaroxaban, apixaban, enoxaparin, delteparin and othersOn the basis of route of administration, the market is segmented into oral and injectableOn the basis of therapeutic area, the market is segmented into cardiovascular diseases, oncology, respiratory, nephrology, CNS and othersOn the basis of procedure, the market is segmented into pre-surgical procedures, post-surgical procedures, kidney dialysis and heart valve replacementOn the basis of type, the market is segmented into generics and brandedOn the basis of end user, the market is segmented into hospitals, clinics, homecare, ambulatory surgical centers and othersOn the basis of distribution channel, the market is segmented into hospital pharmacy, retail pharmacy and online pharmacyCompetitive Analysis: Europe Anticoagulation Therapy MarketSome of the major players operating in the Europe anticoagulation therapy market are Hikma Pharmaceuticals PLC, Mylan N.V., Teva Pharmaceutical Industries Ltd., Novartis AG, Eisai Co., Ltd., Pfizer Inc., Sanofi, F. Hoffmann-La Roche Ltd, Fresenius Kabi AG, Aspen Holdings, Shanghai Fosun Pharmaceutical（Group）Co., Ltd. , Cipla Inc, Johnson & Johnson Services, Inc., Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, DAIICHI SANKYO COMPANY, LIMITED, Eagle Pharmaceuticals, Inc., Endo Pharmaceuticals Inc, Mitsubishi Tanabe Pharma Corporation, Portola Pharmaceuticals, Inc., Taro Pharmaceutical Industries Ltd., among others.Get Detailed Table of Contents @ https://www.databridgemarketresearch.com/toc/?dbmr=europe-anticoagulation-therapy-marketRecent DevelopmentsIn September 2018, Sanofi announced Health got Canada approval for Lovenox’s (enoxaparin sodium) new indication toprevent thrombus formation in the extra-corporeal circulation during haemodialysis in patients who are having end stage kidney disease (ESKD).
This will attract the potential consumers helping in the growth of the company.In August 2018, Bayer AG received the European Commission (EC) approval for Xarelto (rivaroxaban) 2.5 mg.
It is indicated for reduction of chances of cardiovascular situations such as stroke/ heart attack in patients with chronic coronary artery disease (CAD), cardiovascular (CV) death, and peripheral artery disease (PAD).
This approval will help the company to develop anticoagulant business in European countries.In June 2015, Daiichi Sankyo Company, Limited received the EU approval for LIXIANA (edoxaban).
Epidermal Growth Factor Receptor Inhibitors Market Epidermal growth factor receptor is a tyrosine kinase receptor which is responsible for cell growth.
The uncontrolled cell growth of cancer cells are characterized by high levels of epidermal growth factor receptors caused by mutation in responsible genes for production of these proteins.
EGFR inhibitors are the drugs that block the receptors and inhibit the cell growth for a long duration of time.
EGFR inhibitors are mostly used for treatment of lung cancer, liver cancer, breast cancer, collateral cancer among others.According to World Health Organization (WHO), approximately 9.6 million deaths are reported in 2018 by cancer which includes lung, prostate, stomach and liver cancer as the most common types of cancers.
Epidermal growth factor receptor inhibitors are a potent class of drugs for treatment of these major cancers.Market DriversHigh research and development of novel EGFR inhibitors drives the market growthIncreasing incidence rate of cancer worldwide will drive the market growthAdoption of harsh lifestyle and rising consumption of alcohol and tobacco increases causes number of cancers; this factor will also uplift the market growthIncreasing geriatric population developing different diseased conditions demand EGFR inhibitors therapies which will boost the growth of the market in the forecast periodGet Exclusive Sample Report: @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-epidermal-growth-factor-receptor-inhibitors-market Scope of the Epidermal Growth Factor Receptor Inhibitors MarketCurrent and future of Epidermal Growth Factor Receptor Inhibitors Market outlook in the developed and emerging marketsThe segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast periodRegions/Countries that are expected to witness the fastest growth rates during the forecast periodThe latest developments, market shares, and strategies that are employed by the major market playersGlobal Epidermal Growth Factor Receptor Inhibitors Market By Application (Lung Cancer, Liver Cancer, Breast Cancer, Others), Drugs (Cetuximab, Erlotinib, Gefitinib, Others), Route of Administration (Oral, Injectable, Others), End Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) - Industry Trends and Forecast to 2026 Browse Related Report Here:North America Psychedelic Drugs MarketU.S.
Warts Treatment MarketSome of the leading key players profiled in this study:Few of the major competitors currently working in the global epidermal growth factor receptor inhibitors market are AstraZeneca, F. Hoffmann-La Roche Ltd, Pfizer Inc., Spectrum Pharmaceuticals, Inc., CULLINAN ONCOLOGY, LLC, TAIHO PHARMACEUTICAL CO., LTD., Lutris Pharma, Boehringer Ingelheim International GmbH, Puma Biotechnology, IncApollomics, Inc., Hutchison MediPharma Limited, Genentech, Inc., ASLAN Pharmaceuticals, DAIICHI SANKYO COMPANY, LIMITED, Hutchison China MediTech Limited, Sihuan Pharmaceutical Holdings Group Ltd, Astellas Pharma Inc., Celldex Therapeutics, YUHAN, Johnson & Johnson Services, Inc. among others.
11 February 2020 - Global Human Growth Hormone (HGH) Market is anticipated to witness an exponential growth in the forecast period.
Human growth hormone is mainly responsible for regeneration and growth among humans and stimulates cell reproduction.
Factors such as presence of a large pool of patients, technological advancements, demand for better-quality and cost-effective human growth hormones, increasing compliance for human growth hormone drugs and massive unexplored markets in the developing economies, such as China and India.Furthermore, advanced research and development services, and new drug developments by the key companies, increasing occurrences of human growth hormone deficiency diseases, and growing aged population are likely to propel the human growth hormone industry in the forthcoming period.
Human growth hormone (HGH) industry is anticipated to expand at a CAGR of 7.5% in the upcoming period as the scope, product types, and its applications are increasing across the globe.Human growth hormone market could be explored by route administration, application, distribution channel, and geography.
It is likely to witness substantial growth in the years to come.
The key factors that could be attributed to the growth of the market include the preference for the subcutaneous technique is rising as it leads to the important growth in development rates and low occurrence of antibody progress.
